Satellos Bioscience Inc.
MSCLF
$0.4284
$0.01934.72%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 20.21% | 39.06% | 116.13% | 175.48% | 277.61% |
| Gross Profit | -20.21% | -39.06% | -116.13% | -175.48% | -277.61% |
| SG&A Expenses | 8.00% | 1.84% | 21.90% | 62.73% | 91.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.77% | 26.43% | 77.43% | 126.84% | 188.02% |
| Operating Income | -16.77% | -26.43% | -77.43% | -126.84% | -188.02% |
| Income Before Tax | -33.06% | -37.27% | -74.70% | -96.33% | -79.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.62% | -37.67% | -74.70% | -96.26% | -79.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.62% | -37.67% | -74.70% | -96.26% | -79.44% |
| EBIT | -16.77% | -26.43% | -77.43% | -126.84% | -188.02% |
| EBITDA | -16.75% | -26.39% | -77.38% | -127.10% | -192.11% |
| EPS Basic | -9.15% | -13.39% | -33.23% | -2.42% | 24.44% |
| Normalized Basic EPS | 6.49% | 2.05% | -16.48% | -25.28% | 0.54% |
| EPS Diluted | -9.15% | -13.39% | -33.23% | -2.42% | 24.44% |
| Normalized Diluted EPS | 6.49% | 2.05% | -16.48% | -25.28% | 0.54% |
| Average Basic Shares Outstanding | 26.47% | 22.95% | 32.84% | 64.37% | 129.33% |
| Average Diluted Shares Outstanding | 26.47% | 22.95% | 32.84% | 64.37% | 129.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |